Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Astrana Health, Inc. Reports Fourth Quarter and Year-End 2024 Results

      Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.)

      News provided by

      Astrana Health, Inc.

      Feb 27, 2025, 16:27 ET

      Share this article

      Share this article


      Company to Host Conference Call on Thursday, February 27, 2025, at 2:30 p.m. PT/5:30 p.m. ET

      ALHAMBRA, Calif., Feb. 27, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the fourth quarter and year ended December 31, 2024.

      "Astrana Health's strong performance in 2024 highlights the strength of our patient-centered, payer-agnostic platform and our unwavering commitment to delivering high-quality, accessible care. Our significant growth and geographic expansion, alongside robust financial performance, are a direct result of our disciplined execution across the four pillars of the Astrana playbook, " said President and CEO of Astrana, Brandon K. Sim.

      "Looking ahead, we remain focused on growing membership sustainably, further improving quality of care for our membership while responsibly managing costs, growing the 73% of our capitated revenue that now comes from full-risk arrangements, and driving operating leverage and integration of recently acquired assets. We are confident that our platform, combined with our proven ability to navigate industry headwinds and a favorable outlook on future reimbursement rates, will continue delivering sustainable, long-term value for all our stakeholders - patients, physicians, providers, payers, and shareholders."

      Financial Highlights for Year Ended December 31, 2024:

      All comparisons are to the year ended December 31, 2023 unless otherwise stated.

      • Total revenue of $2,034.5 million, up 47% from $1,386.7 million
      • Care Partners revenue of $1,949.0 million, up 52% from $1,284.1 million
      • Net income attributable to Astrana of $43.1 million, compared to $60.7 million
      • Earnings per share - diluted ("EPS - diluted") of $0.90, compared to $1.29 per share
      • Adjusted EBITDA(1) of $170.4 million, up 16% from $146.6 million

      (1) See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information.

      Financial Highlights for the Fourth Quarter 2024:

      All comparisons are to the quarter ended December 31, 2023 unless otherwise stated.

      • Total revenue of $665.2 million, up 88% from $353.0 million
      • Care Partners revenue of $647.7 million, up 98% from $326.8 million
      • Net loss attributable to Astrana of $7.0 million, compared to income of $12.4 million
      • (Loss) earnings per share - basic and diluted ("EPS - basic and diluted") of $(0.15), compared to $0.26 per share
      • Adjusted EBITDA(1) of $35.0 million, up 21% from $29.0 million

      (1) See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information.

      Recent Operating Highlights

      • In late 2024, Astrana began a Care Enablement partnership with Provider HealthLink, or PHL, a provider network in Georgia. Astrana plans to support PHL in serving approximately 10,000 Medicare Advantage members, and the group is expected to be onboarded onto Astrana's Care Enablement platform in the first half of 2025.
      • On February 26, 2025, the Company amended its credit agreement with Truist Bank, in its capacities as administrative agent for the lenders (the "Second Amended and Restated Credit Agreement"). The Second Amended and Restated Credit Agreement provides for (a) a five-year revolving credit facility to the Company of $300.0 million which includes a letter of credit sub-facility of up to $100.0 million and a swingline loan sub-facility of $25.0 million, (b) a five-year term loan A credit facility to the Company of $250.0 million and (c) a five-year delayed draw term loan credit facility to the Company of $745.0 million. The term loan A and revolving credit facilities will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, pay transactions costs and expenses arising in connection with the Second Amended and Restated Credit Agreement, and provide for working capital needs and other general corporate purposes, and, in addition to the foregoing, the revolving credit facility will also be used to finance certain future permitted acquisitions and permitted investments and capital expenditures. The delayed draw term loan facility will be used to finance the acquisition of certain assets contemplated by that certain asset and equity purchase agreement, dated November 8, 2024, by and among the Company, Prospect Medical Holdings, Inc., in its capacity as the seller representative, and certain other parties party thereto, and to pay any fees and expenses associated therewith.
      • Eight of Astrana's affiliates have been recognized as Elite status recipients in the 2024 Standards of Excellence ("SOE") survey by America's Physician Groups ("APG"), attaining the highest Elite five-star status in all categories. This annual comprehensive survey is administered by APG to evaluate which physician groups are best positioned to provide coordinated, patient-centered, and cost-effective care.
      • On January 17, 2025, the Company repurchased 300,000 shares of the Company's common stock from Allied Physicians of California ("APC"), pursuant to a stock repurchase agreement, for an aggregate purchase price of approximately $10.6 million, based on a purchase price per share of $35.17, which was the closing price of the Company's common stock on Nasdaq on the date the agreement was executed. APC is a consolidated affiliate of the Company.

      Segment Results for the Year Ended December 31, 2024:

      All comparisons are to the year ended December 31, 2023 unless otherwise stated.



      Year Ended December 31, 2024


      (in thousands)


      Care
      Partners



      Care
      Delivery



      Care
      Enablement



      Other



      Intersegment
      Elimination



      Corporate
      Costs



      Consolidated
      Total


      Total revenues


      $

      1,949,033



      $

      136,668



      $

      155,448



      $

      —



      $

      (206,609)



      $

      —



      $

      2,034,540


      % change vs. prior year



      52

      %



      16

      %



      14

      %



































      Cost of services



      1,633,021




      109,672




      83,720




      —




      (63,261)




      —




      1,763,152


      General and administrative(1)



      174,774




      26,893




      53,461




      —




      (143,433)




      70,343




      182,038


      Total expenses



      1,807,795




      136,565




      137,181




      —




      (206,694)




      70,343




      1,945,190
























      Income (loss) from operations


      $

      141,238



      $

      103



      $

      18,267



      $

      —



      $

      85


      (2)

      $

      (70,343)



      $

      89,350


      % change vs. prior year



      54

      %



      (98)

      %



      (4)

      %















      (1)

      Balance includes general and administrative expenses and depreciation and amortization.



      (2)

      Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.

      2025 Guidance:

      Astrana is providing the following guidance for total revenue and Adjusted EBITDA, based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2025. The following guidance includes approximately $15 million in expected costs associated with continued strategic investments in automation and AI, as well as ongoing and expected integration costs associated with planned acquisitions, but does not include contributions from any acquisitions which have not yet closed.



      2025 Guidance Range


      ($ in millions)


      Low



      High


      Total revenue


      $

      2,500



      $

      2,700


      Adjusted EBITDA


      $

      170



      $

      190


      See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

      Conference Call and Webcast Information:

      Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (February 27, 2025), during which management will discuss the results of the fourth quarter and year ended December 31, 2024. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

      U.S. & Canada (Toll-Free):



      +1 (877) 858-9810


      International (Toll):



      +1 (201) 689-8517


      The conference call can also be accessed via webcast at:
      https://event.choruscall.com/mediaframe/webcast.html?webcastid=VvYSvHe6

      An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov. 

      Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

      Note About Consolidated Entities

      The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.

      Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share

      As of the date of this press release, 41,048 holdback shares have not been issued to certain former shareholders of the Company's subsidiary, Astrana Health Management, Inc. ("AHM"), formerly known as Network Medical Management, Inc., who were AHM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana's common stock and warrants as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among Astrana, AHM, Apollo Acquisition Corp. ("Merger Subsidiary") and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into AHM, with AHM as the surviving corporation. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and Astrana is legally obligated to issue these shares in connection with the merger.

      Shares of Astrana's common stock owned by Allied Physicians of California, a Professional Medical Corporation ("APC"), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.

      About Astrana Health,  Inc.

      Astrana Health, Inc. ("Astrana") is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, Astrana operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. Together with our affiliated physician groups and consolidated entities, we provide coordinated outcomes-based medical care in a cost-effective manner.

      Headquartered in Alhambra, California, Astrana serves over 10,000 providers and approximately 1.1 million patients in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), a network of risk-bearing organizations ("RBOs") that encompasses independent practice associations ("IPAs"), accountable care organizations ("ACOs"), and state-specific entities such as Restricted Knox-Keene licensed health plans in California, and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.

      Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending December 31, 2025, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, and successful implementation of strategic growth plans, acquisition strategy, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's last Annual Report on Form 10-K and any subsequent quarterly reports on Form 10-Q filed with the SEC. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

      FOR MORE INFORMATION, PLEASE CONTACT:

      Investor Relations

      (626) 943-6491
      Asher Dewhurst, ICR Westwicke
      [email protected] 

      ASTRANA HEALTH, INC.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)




      December 31,
      2024



      December 31,
      2023




      (Unaudited)





      Assets














      Current assets







      Cash and cash equivalents


      $

      288,455



      $

      293,807


      Investment in marketable securities



      2,378




      2,498


      Receivables, net



      226,739




      76,780


      Receivables, net – related parties



      50,257




      58,980


      Income taxes receivable



      19,316




      10,657


      Other receivables



      3,656




      1,335


      Prepaid expenses and other current assets



      22,861




      17,450









      Total current assets



      613,662




      461,507









      Non-current assets







      Property and equipment, net



      14,274




      7,171


      Intangible assets, net



      126,179




      71,648


      Goodwill



      437,651




      278,831


      Income taxes receivable



      15,943




      15,943


      Loans receivable, non-current



      51,266




      26,473


      Investments in other entities – equity method



      39,319




      25,774


      Investments in privately held entities



      8,896




      6,396


      Restricted cash



      646




      345


      Operating lease right-of-use assets



      32,601




      37,396


      Other assets



      16,021




      1,877









      Total non-current assets



      742,796




      471,854









      Total assets(1)


      $

      1,356,458



      $

      933,361









      Liabilities, Mezzanine Deficit, and Stockholders' Equity














      Current liabilities







      Accounts payable and accrued expenses


      $

      114,650



      $

      59,949


      Fiduciary accounts payable



      8,223




      7,737


      Medical liabilities



      209,039




      106,657


      Dividend payable



      638




      638


      Finance lease liabilities



      554




      646


      Operating lease liabilities



      5,350




      4,607


      Current portion of long-term debt



      9,375




      19,500


      Other liabilities



      19,343




      18,940









      Total current liabilities



      367,172




      218,674









      Non-current liabilities







      Deferred tax liability



      4,555




      4,072


      Finance lease liabilities, net of current portion



      607




      1,033


      Operating lease liabilities, net of current portion



      30,654




      36,289


      Long-term debt, net of current portion and deferred financing costs



      425,299




      258,939


      Other long-term liabilities



      14,003




      3,586









      Total non-current liabilities



      475,118




      303,919









      Total liabilities(1)



      842,290




      522,593









      Commitments and contingencies














      Mezzanine deficit







      Non-controlling interest in Allied Physicians of California, a Professional
         Medical Corporation ("APC")



      (202,558)




      (205,883)









      Stockholders' equity







      Preferred stock, $0.001 par value per share; 5,000,000 shares authorized as of
      December 31, 2024 and December 31, 2023







      Series A Preferred stock, zero authorized and issued and zero outstanding as of
      December 31, 2024 and 1,111,111 authorized and issued and zero outstanding as
      of December 31, 2023



      —




      —


      Series B Preferred stock, zero authorized and issued and zero outstanding as of
      December 31, 2024 and 555,555 authorized and issued and zero outstanding as of
      December 31, 2023



      —




      —


      Common stock, $0.001 par value per share; 100,000,000 shares authorized,
      47,929,872 and 46,843,743 shares issued and outstanding, excluding 10,603,849
      and 10,584,340 treasury shares, as of December 31, 2024 and December 31, 2023,
      respectively



      48




      47


      Additional paid-in capital



      426,389




      371,037


      Retained earnings



      286,283




      243,134


      Total stockholders' equity



      712,720




      614,218









      Non-controlling interest



      4,006




      2,433









      Total  equity



      716,726




      616,651









      Total liabilities, mezzanine deficit, and stockholders' equity


      $

      1,356,458



      $

      933,361




      (1)

      The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $761.4 million and $540.8 million as of December 31, 2024 and December 31, 2023, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $253.7 million and $146.0 million as of December 31, 2024 and December 31, 2023, respectively. These VIE balances do not include $224.9 million of investment in affiliates and $48.5 million of amounts due to affiliates as of December 31, 2024, and $273.2 million of investment in affiliates and $107.3 million of amounts due to affiliates as of December 31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets.

      ASTRANA HEALTH, INC.

      CONSOLIDATED STATEMENTS OF INCOME

      (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

      (UNAUDITED)




      Three Months Ended
      December 31,



      Year Ended
      December 31,




      2024



      2023



      2024



      2023


      Revenue













      Capitation, net


      $

      616,900



      $

      309,184



      $

      1,856,785



      $

      1,215,614


      Risk pool settlements and incentives



      28,660




      14,863




      86,224




      63,468


      Management fee income



      5,550




      6,390




      13,979




      38,677


      Fee-for-service, net



      7,743




      18,442




      62,331




      59,658


      Other revenue



      6,356




      4,157




      15,221




      9,244















      Total revenue



      665,209




      353,036




      2,034,540




      1,386,661















      Operating expenses













      Cost of services, excluding depreciation and amortization



      614,730




      314,055




      1,763,152




      1,171,703


      General and administrative expenses



      41,633




      37,949




      154,111




      112,597


      Depreciation and amortization



      8,126




      4,902




      27,927




      17,748















      Total expenses



      664,489




      356,906




      1,945,190




      1,302,048















      Income from operations



      720




      (3,870)




      89,350




      84,613















      Other income (expense)













      Income from equity method investments



      1,564




      2,475




      4,451




      5,579


      Interest expense



      (8,069)




      (5,422)




      (33,097)




      (16,102)


      Interest income



      3,221




      4,591




      14,508




      14,208


      Unrealized gain (loss) on investments



      316




      1,294




      731




      (4,581)


      Other income



      353




      1,856




      4,875




      6,121















      Total other (expense) income, net



      (2,615)




      4,794




      (8,532)




      5,225















      (Loss) income before provision for income taxes



      (1,895)




      924




      80,818




      89,838















      Provision for income taxes



      5,882




      1,018




      30,886




      31,989















      Net (loss) income



      (7,777)




      (94)




      49,932




      57,849















      Net (loss) income attributable to noncontrolling interests



      (826)




      (12,450)




      6,783




      (2,868)















      Net (loss) income attributable to Astrana Health, Inc.


      $

      (6,951)



      $

      12,356



      $

      43,149



      $

      60,717















      (Loss) earnings per share – basic


      $

      (0.15)



      $

      0.26



      $

      0.91



      $

      1.30















      (Loss) earnings per share – diluted


      $

      (0.15)



      $

      0.26



      $

      0.90



      $

      1.29


      EBITDA

      Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA as well as the reconciliation to Adjusted EBITDA margin for the three months and years ended December 31, 2024 and 2023. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.



      Three Months Ended
      December 31,



      Year Ended
      December 31,



      (in thousands)


      2024



      2023



      2024



      2023



      Net (loss) income


      $

      (7,777)



      $

      (94)



      $

      49,932



      $

      57,849



      Interest expense



      8,069




      5,422




      33,097




      16,102



      Interest income



      (3,221)




      (4,591)




      (14,508)




      (14,208)



      Provision for income taxes



      5,882




      1,018




      30,886




      31,989



      Depreciation and amortization



      8,126




      4,902




      27,927




      17,748



      EBITDA


      $

      11,079



      $

      6,657



      $

      127,334



      $

      109,480

















      Income from equity method
      investments



      (1,564)




      (1,989)




      (4,451)




      (5,149)



      Other, net



      10,288


      (4)


      4,721


      (5)


      12,951


      (2)


      6,228


      (3)

      Stock-based compensation



      15,235




      8,676




      34,536




      22,040



      APC excluded assets costs



      —




      10,949




      —




      13,988



      Adjusted EBITDA


      $

      35,038



      $

      29,014



      $

      170,370



      $

      146,587

















      Total Revenue


      $

      665,209



      $

      353,036



      $

      2,034,540



      $

      1,386,661

















      Adjusted EBITDA margin(1)



      5

      %



      8

      %



      8

      %



      11

      %




      (1)

      The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.



      (2)

      Other, net for the year ended December 31, 2024 relates to transaction costs incurred for our investments and tax restructuring fees, anticipated recoveries from one time losses relating to third party payer payments associated with the Collaborative Health Systems, LLC ("CHS") transaction, financial guarantee via a letter of credit that we provided almost three years ago in support of two local provider-led ACOs, reimbursement from a related party of the Company for taxes associated with the December 2023 Excluded Assets Spin-off, non-cash gain on debt extinguishment related to one of our promissory note payables, non-cash realized loss from sale of one of our marketable equity securities, non-cash changes related to change in the fair value of our call option, change in the fair value of our financing obligation to purchase the remaining equity interests in one of our investments, changes in the fair value of our contingent liabilities, and changes in the fair value of the Company's Collar Agreement.



      (3)

      Other, net for the year ended December 31, 2023 consists of nonrecurring transaction costs and tax restructuring fees incurred, non-cash gains and losses related to the changes in the fair value of our financing obligation to purchase the remaining equity interests, contingent liabilities, and the Company's Collar Agreement relating to interest on the Revolver Loan, and excise tax related to a nonrecurring buyback of the Company's stock from APC.



      (4)

      Other, net for the three months ended December 31, 2024 relates to transaction costs incurred for our investments, to anticipated recoveries from one time losses relating to third party payer payments associated with the CHS transaction, and non-cash change in the fair value of our call option.



      (5)

      Other, net for the three months and year ended December 31, 2023 consists of nonrecurring transaction costs and tax restructuring fees incurred, non-cash gains and losses related to the changes in the fair value of our financing obligation to purchase the remaining equity interests, contingent liabilities, and the Company's Collar Agreement, and excise tax related to a nonrecurring buyback of the Company's stock from APC.

      Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA




      2025 Guidance Range


      (in thousands)


      Low



      High


      Net income


      $

      62,500



      $

      73,500


      Interest expense, net



      16,000




      19,000


      Provision for income taxes



      34,000




      40,000


      Depreciation and amortization



      32,500




      32,500


      EBITDA



      145,000




      165,000









      Income from equity method investments



      (5,500)




      (5,500)


      Other, net



      9,500




      9,500


      Stock-based compensation



      21,000




      21,000


      Adjusted EBITDA


      $

      170,000



      $

      190,000


      Use of Non-GAAP Financial Measures

      This press release contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.

      The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate both EBITDA and Adjusted EBITDA differently, limiting the usefulness of these measures for comparative purposes. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

      SOURCE Astrana Health, Inc.

      Modal title

      Also from this source

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center, part of Astrana Health, Inc. (NASDAQ: ASTH), earned multiple national honors from Healthgrades, the leading...

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      Earnings Forecasts & Projections

      Earnings Forecasts & Projections

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.